Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal AF Safety in ERT-Naive Children with Fabry Disease
NCT01363492Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2011
- Primary completion
- Apr 2013
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started May 2011; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01363492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363492.